Why We Chose Veeva Vault CRM: BioNTech, Boehringer Ingelheim, and GSK

At Veeva Commercial Summit, Europe, in November 2024, Boehringer Ingelheim became the fourth top 20 biopharma to commit to Vault CRM, joining Bayer, GSK, and Novo Nordisk. More than 30 companies are live on Vault CRM and seven early migrators have transitioned from Veeva CRM.

Three committed companies joined me on stage to share their thinking and progress since Vault CRM was announced two years ago:

• BioNTech discussed why it decided to bring together R&D, medical, and commercial on the Vault platform. It sought an IT architecture that reflects how its different business domains collaborate, with simplicity, business enablement, and seamless integration between data and systems as its guiding principles. Noting that the company “wanted to leverage Veeva’s knowledge of the system and industry expertise from the start”, BioNTech’s Global Head of Digital and IT Raimond Jähn said that his team implemented Veeva Medical Solutions “at light speed”, with Commercial to follow. “Veeva’s latest advances will boost field productivity, increase compliance, and speed up medical, legal, and regulatory (MLR) review, enabling easier AI adoption in life sciences,” added Jähn.
• Boehringer Ingelheim shared why the Vault platform is integral to the company’s future expansion as its teams prepare to launch 25 new treatments by 2030. Describing the move to Vault CRM as a “seismic decision”, Head of Global Customer Experience Excellence and Business Steering Uday Bose explained that a key factor was avoiding disruption at all costs. Choosing Vault CRM delivers a consistent user experience for reps and MSLs, and so requires minimal retraining for field forces. As all content will be deployed through Vault CRM, brand managers can remain focused on launching assets to patients. “Veeva’s knowledge of our customers, sector, regulatory environment, challenges, and opportunities is unique. Nobody can offer that starting from day one,” he said.
• After announcing its decision to move to Vault CRM in late 2023, GSK shared that one year on, the migration process is on track: more than 15,000 users in 50+ countries are expected to be live by late 2025. Going early has allowed the organization to concentrate on its strategic priorities. “A year later, I still feel there is no second ready-to-go life sciences CRM. That means my team has spent zero hours running beauty parades in the last year,” said Kieron Scrutton, senior vice president of global medical affairs digital and technology, and tech governance risk and compliance. “The broader team has been entirely focused on the digital data and AI transformation that we’re making in GSK.”

Hear the latest advancements in Vault CRM Suite, focused on customer centricity, simplification, AI in CRM, and unlocking innovation.